Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Core outcome sets for use in effectiveness trials involving people with bipolar and schizophrenia in a community-based setting (PARTNERS2): study protocol for the development of two core outcome sets.

Keeley T, Khan H, Pinfold V, Williamson P, Mathers J, Davies L, Sayers R, England E, Reilly S, Byng R, Gask L, Clark M, Huxley P, Lewis P, Birchwood M, Calvert M.

Trials. 2015 Feb 12;16:47. doi: 10.1186/s13063-015-0553-0.

2.

Acceleration-based joint stability parameters for total knee arthroplasty that correspond with patient-reported instability.

Roberts D, Khan H, Kim JH, Slover J, Walker PS.

Proc Inst Mech Eng H. 2013 Oct;227(10):1104-13. doi: 10.1177/0954411913493724. Epub 2013 Jul 25.

PMID:
23886970
3.

A comparison of patient and tumour characteristics in two UK bladder cancer cohorts separated by 20 years.

Bryan RT, Zeegers MP, van Roekel EH, Bird D, Grant MR, Dunn JA, Bathers S, Iqbal G, Khan HS, Collins SI, Howman A, Deshmukh NS, James ND, Cheng KK, Wallace DM.

BJU Int. 2013 Jul;112(2):169-75. doi: 10.1111/bju.12032. Epub 2013 Mar 4.

4.

The potential of accelerometers in the evaluation of stability of total knee arthroplasty.

Khan H, Walker PS, Zuckerman JD, Slover J, Jaffe F, Karia RJ, Kim JH.

J Arthroplasty. 2013 Mar;28(3):459-62. doi: 10.1016/j.arth.2012.07.025. Epub 2012 Nov 2.

PMID:
23122873
5.

Genetic marker polymorphisms on chromosome 8q24 and prostate cancer in the Dutch population: DG8S737 may not be the causative variant.

Zeegers MP, Khan HS, Schouten LJ, van Dijk BA, Goldbohm RA, Schalken J, Shajahan S, Pearlman A, Oddoux C, van den Brandt PA, Ostrer H.

Eur J Hum Genet. 2011 Jan;19(1):118-20. doi: 10.1038/ejhg.2010.133. Epub 2010 Aug 11.

6.

Identification of seven new prostate cancer susceptibility loci through a genome-wide association study.

Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, Muir K, Hopper JL, Henderson BE, Haiman CA, Schleutker J, Hamdy FC, Neal DE, Donovan JL, Stanford JL, Ostrander EA, Ingles SA, John EM, Thibodeau SN, Schaid D, Park JY, Spurdle A, Clements J, Dickinson JL, Maier C, Vogel W, Dörk T, Rebbeck TR, Cooney KA, Cannon-Albright L, Chappuis PO, Hutter P, Zeegers M, Kaneva R, Zhang HW, Lu YJ, Foulkes WD, English DR, Leongamornlert DA, Tymrakiewicz M, Morrison J, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Saunders EJ, Page EC, Sawyer EJ, Edwards SM, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Southey MC, Lophatananon A, Liu JF, Kolonel LN, Le Marchand L, Wahlfors T, Tammela TL, Auvinen A, Lewis SJ, Cox A, FitzGerald LM, Koopmeiners JS, Karyadi DM, Kwon EM, Stern MC, Corral R, Joshi AD, Shahabi A, McDonnell SK, Sellers TA, Pow-Sang J, Chambers S, Aitken J, Gardiner RA, Batra J, Kedda MA, Lose F, Polanowski A, Patterson B, Serth J, Meyer A, Luedeke M, Stefflova K, Ray AM, Lange EM, Farnham J, Khan H, Slavov C, Mitkova A, Cao G; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF.

Nat Genet. 2009 Oct;41(10):1116-21. doi: 10.1038/ng.450. Epub 2009 Sep 20.

Supplemental Content

Loading ...
Support Center